2022
DOI: 10.1523/jneurosci.1657-21.2021
|View full text |Cite
|
Sign up to set email alerts
|

Chronic Behavioral Manipulation via Orally Delivered Chemogenetic Actuator in Macaques

Abstract: Oyama et al. Chronic behavioral manipulation via orally delivered chemogenetic actuator in macaques

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
9
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1
1

Relationship

1
9

Authors

Journals

citations
Cited by 18 publications
(11 citation statements)
references
References 47 publications
2
9
0
Order By: Relevance
“…Rats were then trained and tested as shown in Figure 5A . Following the initial instrumental training and outcome devaluation testing ( Figure 5—figure supplement 1A–C for LC: vlOFC and Figure 5—figure supplement 2A–C for LC: A32 ), both groups were further divided into two according to their initial performance: one group that would receive vehicle (Veh; n=12 for OFC-injected rats; n=8 for A32-injected rats) and one group that would receive deschloroclozapine dihydrochloride (DCZ; n=13 for OFC-injected rats; n=9 for A32-injected rats), a high affinity and selective DREADDs agonist ( Nagai et al, 2020 ; Nentwig et al, 2021 ; Oyama et al, 2022 ), during the reversal training.…”
Section: Resultsmentioning
confidence: 99%
“…Rats were then trained and tested as shown in Figure 5A . Following the initial instrumental training and outcome devaluation testing ( Figure 5—figure supplement 1A–C for LC: vlOFC and Figure 5—figure supplement 2A–C for LC: A32 ), both groups were further divided into two according to their initial performance: one group that would receive vehicle (Veh; n=12 for OFC-injected rats; n=8 for A32-injected rats) and one group that would receive deschloroclozapine dihydrochloride (DCZ; n=13 for OFC-injected rats; n=9 for A32-injected rats), a high affinity and selective DREADDs agonist ( Nagai et al, 2020 ; Nentwig et al, 2021 ; Oyama et al, 2022 ), during the reversal training.…”
Section: Resultsmentioning
confidence: 99%
“…Figure 5A-C for LC: OFC and Suppl. Figure 6A-C for LC: mPFC ), they were divided in two groups according to their initial performance: one group that would receive vehicle (Veh, -) during reversal training and one group that would receive deschloroclozapine dihydrochloride (DCZ, +), a high affinity and selective agonist for hM4D (Nagai et al, 2020; Nentwig et al, 2021; Oyama et al, 2022).…”
Section: Resultsmentioning
confidence: 99%
“…Importantly, also as in previous reports 12 , 31 – 33 , we did not observe any discernible side effects on brain activity or animal behavior. In the current study, we administered DCZ intramuscularly, but it can also be administered orally and has been proven to activate hM4Di chronically for more than two weeks with repetitive doses 34 . Although further safety testing is needed before moving on to clinical trials, these characteristics suggest that DCZ may be a safe and effective DREADD actuator that might be used in future clinical trials.…”
Section: Discussionmentioning
confidence: 99%